Fresh science and technology news from New Hampshire
Provided by AGP
Cytospire Therapeutics announces oversubscribed £61 million ($83m) Series A financing to advance pipeline of first-in-class pan-gamma delta T cell engagers into clinical trials for the treatment of cancer
- Series A financing led by 4BIO Capital, with major new investors Servier Ventures, Sound Bioventures, British Business Bank and Criteria Bio Ventures, supported by existing investors Abingworth and LifeArc Ventures
- Cytospire’s novel pan-gamma T cell engagers offer a compelling solution to the efficacy and safety challenges faced by conventional T cell engagers
- New financing will accelerate Cytospire’s pipeline in solid and liquid tumours, including advancement of lead program, CYT X300 targeting EGFR-positive cancers, to clinical proof-of-concept
- Secures the first-ever investment from Servier’s newly formed corporate venture fund
London, UK – May 05, 2026. Cytospire Therapeutics (‘Cytospire’), a UK based biotech developing differentiated multispecific immune cell engager antibodies designed to enhance and direct the activity of the body’s own immune system, today announces the closing of an oversubscribed £61 million ($83 million) Series A financing supported by a strong syndicate of new and existing biotech investors.
Cytospire will use the proceeds to advance its pipeline of first-in-class pan-gamma delta T cell engagers, including its lead programme, CYT X300, which is currently being advanced through IND-enabling preclinical studies and GMP manufacturing. A first-in-human clinical study is being planned to evaluate CYT X300 as a treatment for EGFR-positive solid tumours, such as colorectal, head and neck and non-small cell lung cancers.
The round was led by 4BIO Capital, with significant investment from new syndicate members Servier Ventures, British Business Bank, Sound Bioventures and Criteria Bio Ventures, as well as from existing investors Abingworth and LifeArc Ventures. Modi Ventures, Medical Incubator Japan and Pathway Bioventures also join the round as new investors. It is the first investment from Servier Ventures, the newly established corporate venture fund of Servier, which aims to advance science and unlock tomorrow’s breakthrough therapies for the benefit of patients.
“We are excited to write the next chapter of Cytospire’s story with this fantastic group of specialist investors,” said Natalie Mount, Chief Executive Officer of Cytospire Therapeutics. “Immune cell engagers are an important type of cancer immunotherapy, but we know that there are significant limitations from both an efficacy and safety perspective with conventional CD3 T cell engagers. We are building on the growing body of translational and clinical data showing gamma delta T cells are critical components of the anti-cancer immune response, with biology ideally suited to novel cell engagers. The significant fundraise that we are announcing today reflects the quality of our team and our science, and the huge potential of our pan-gamma delta T cell engagers”.
Cytospire’s pan-gamma delta T cell engagers are uniquely engineered to target all gamma delta T cells rather than specific subtypes. Through this approach, Cytospire seeks to overcome patient heterogeneity and generate broader, more effective anti‑tumour immune responses through the activation of both tissue/tumour resident and blood resident effector cells.
“Cancer immunotherapy has provided a step-change in treatment for many types of cancer over the past decade, but we need to do more,” commented Owen Smith, Partner at 4BIO Capital and Board Member at Cytospire. “We are proud to have led the Series A alongside this strong investor syndicate. It is exciting to see the company advance CYT X300 and its pioneering portfolio of cancer therapies into the clinic to improve outcomes for cancer patients.”
“As the founding investor in Cytospire, we are strong believers in the potential of gamma delta T cell-based therapies to change the treatment paradigm in multiple cancer indications” added Bali Muralidhar, Global Head of Life Sciences and Chief Investment Officer at Abingworth and Board Member at Cytospire. “There is a need for novel strategies in the field of immune cell engagers, and we believe that Cytospire is well positioned at the forefront of this exciting space”.
In connection with the financing, Cytospire’s Board of Directors has been strengthened by the appointments of Alexis Vandier (Global Head of Servier Ventures), Carmine Circelli (Investment Director, British Business Bank), and Anna Gran (Principal, Sound Bioventures).
About Cytospire Therapeutics
Cytospire is developing an innovative portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells. Our core technology allows binding and activation of both tissue/tumour and blood resident gamma delta T cells. This opens a path to safer and more efficacious targeting of well-validated antigens that are intractable to CD3 T cell engagers due to toxicity. There are broad opportunities for Cytospire’s gamma delta T cell engagers in solid and haematological malignancies, as well as in autoimmune disease.
Based in London, UK, Cytospire Therapeutics is backed by a strong syndicate of life science investors including Abingworth, 4BIO Capital, Servier Ventures, British Business Bank, Sound Bioventures, LifeArc Ventures and Criteria Bio Ventures.
For more information, visit www.cytospire.com
Contacts
Andrew Fadden, Chief Business Officer
contact@cytospiretx.com
Frazer Hall, Mark Swallow
MEDiSTRAVA
cytospire@medistrava.com
Attachment
Natalie Mount
Chief Executive Officer, Cytospire
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
